Every patient lost carries two costs: the investment already made and the investment required to recover. Readiness economics makes both visible.
Executive brief
Attrition is not only a patient outcome. It is capital leakage.
Clinical trial economics are commonly measured through recruitment spend, enrollment velocity, screen-failure rates, and total study cost. Those measures matter, but they leave a critical financial variable unresolved: whether each participant is sufficiently prepared and supported to sustain participation through the required endpoint.
Investment accumulates with every interaction, screening activity, site visit, procedure, treatment, data point, and support intervention. When a participant leaves, the trial loses the value already invested and may absorb replacement recruitment, site rework, schedule extension, and forecast disruption.
The economic question is therefore larger than the cost of recruitment. It is how much cumulative patient investment is protected when readiness improves and preventable attrition declines.
Patient readiness converts a behavioral condition into a measurable economic input.
The economic chain
Connect readiness to the outcomes finance already understands.
The model begins with medical eligibility, but does not stop there. The Trial Readiness Index identifies whether participation is cognitively, emotionally, behaviorally, and practically sustainable. Primary frictions inform targeted intervention. Measured readiness gain then connects to improved progression probability, investment protected, cost avoidance, and study execution value.
Medical Eligibility → Trial Readiness Index → Primary Readiness Frictions → Targeted Intervention → Readiness Gain → Improved Progression Probability → Investment Protected → Cost Avoidance → Study Execution Value
This chain makes the value case auditable. It shows what changed, why it changed, and where the economic effect should appear.
Trial Readiness Index
Eligibility determines access. Readiness determines productive progression.
The Trial Readiness Index, or TRI, is a structured measure of the conditions that influence whether a medically eligible patient can advance and persist. It can incorporate comprehension, confidence, practical feasibility, caregiver support, emotional state, behavioral capacity, and protocol burden.
Readiness gain measures movement after support is introduced:
Readiness Gain = Current TRI − Baseline TRI
The objective is not to reduce a person to a score. The objective is to make otherwise invisible participation risk detectable, actionable, and measurable before it becomes an expensive operational outcome.
Cumulative patient investment
The financial value of a patient rises at every stage.
A referral carries acquisition cost. A screened patient adds site effort and diagnostic activity. An enrolled participant adds treatment, procedures, monitoring, support, and data-generation cost. A participant approaching completion may represent months or years of accumulated investment.
Cumulative patient investment through any stage can be expressed as:
CPI(s) = Sum of attributable patient investment through stage s
Using the same economic value for an early referral and a late-stage participant conceals the actual exposure. Readiness governance becomes more valuable as cumulative investment grows and the remaining replacement window narrows.
| Stage | Investment accumulated | Primary economic exposure |
|---|---|---|
| Identification and referral | Data, media, outreach, and qualification | Low-quality acquisition and site burden |
| Screening and consent | Site time, tests, education, and decision support | Screen failure and avoidable restart cost |
| Enrollment and treatment | Clinical procedures, treatment, monitoring, and support | Replacement cost and lost data continuity |
| Late participation | Substantial cumulative care, data, and operating investment | High-value attrition and timeline risk |
Investment protected
Quantify the value of preventing avoidable attrition.
Once cumulative patient investment and preventable attrition probability are estimated, the study can calculate the capital currently exposed and the portion a readiness intervention may protect.
Investment at Risk = CPI × Probability of Preventable Attrition
Investment Protected = CPI × Attributable Reduction in Preventable Attrition Probability
The word attributable matters. Readiness cannot claim every retained participant or every avoided delay. A credible value model isolates the change reasonably connected to the intervention and distinguishes it from clinical, operational, and external causes.
Cost avoidance
Protected investment is only the first layer of value.
Preventing attrition can also avoid future activity that would otherwise be required: replacement recruitment, repeated screening, site rework, additional outreach, protocol recovery, and other incremental costs.
Cost Avoided = Activity Avoided × Incremental Cost per Activity
Cost avoidance should use incremental cost, not an inflated share of total program spend. Conservative assumptions create a more credible value case and make the framework usable by clinical operations, finance, procurement, and portfolio leadership.
The terminal denominator
Cost per enrollment ends the calculation too early.
A participant who enrolls but does not produce the required endpoint does not deliver the same study value as one who completes. For that reason, cost per completed participant is the more consequential economic measure.
Cost per Completed Participant = Total Patient Acquisition and Participation Cost ÷ Completed Participants
This denominator exposes a hidden truth. A recruitment program can look efficient on cost per lead or cost per enrollment while completion economics deteriorate. Improving completion can create value even when the recruitment budget remains unchanged because the same investment produces more usable participation.
Execution value
The largest exposure may sit outside direct patient cost.
Attrition can create schedule delay, data risk, enrollment rescue, study extension, milestone disruption, and portfolio reforecasting. These consequences are less certain than direct cost but often larger.
Expected Execution Exposure = Probability of Event × Financial Consequence
Total Readiness Economic Impact = Investment Protected + Cost Avoidance + Execution Value
The framework separates direct, attributable value from probability-weighted execution value. That distinction helps decision-makers understand what is measurable now, what must be modeled, and what should be validated over time.
Disease profiles
The economics change when replacement becomes harder.
Readiness economics should reflect the disease profile, protocol, population, and remaining recruitment opportunity. A uniform model across every trial will miss where exposure truly concentrates.
| Disease profile | Readiness challenge | Economic implication |
|---|---|---|
| Common disease | High apparent supply can conceal silent attrition and weak durability. | Volume may mask a rising cost per completer. |
| Specialty disease | Motivated patients may still face complex treatment, travel, and lifestyle demands. | Higher burden increases the value of preparation and early intervention. |
| Rare disease | Patients may be geographically dispersed, caregiver-dependent, and difficult to replace. | One preventable withdrawal can create material schedule and data exposure. |
Sponsor scorecard
Measure readiness as rigorously as recruitment.
A sponsor scorecard should connect leading readiness signals to downstream operational and economic outcomes. The purpose is not another dashboard. It is a governed line of sight from patient condition to financial consequence.
| Measurement layer | Example metrics | Decision supported |
|---|---|---|
| Readiness | TRI, readiness gain, friction type, barrier resolution | Who needs what intervention before advancement? |
| Progression | Screening completion, consent progression, site handoff quality | Is readiness translating into productive movement? |
| Persistence | Missed activity, burden accumulation, support escalation, withdrawal | Where is completion risk increasing? |
| Economics | Investment at risk, investment protected, cost avoided, cost per completer | What value is the readiness system creating? |
Measurement and validation
Make the business case conservative enough to trust.
Readiness economics should begin with a documented baseline, explicit assumptions, and a defined attribution window. Compare patients, cohorts, sites, or time periods where the design supports it. Track both readiness movement and the operational event the intervention is expected to influence.
Report a range when uncertainty is material. Separate realized savings from modeled exposure. Avoid claiming value for clinical outcomes or external conditions the readiness system could not control. The strongest model is not the one with the largest number. It is the one finance and operations can interrogate and still use.
Credibility compounds. Conservative math can make readiness governable across a portfolio.
Conclusion
The value is not more activity. It is more productive participation.
Patient readiness gives sponsors a way to connect experience quality with clinical trial economics. It shows how a participant's ability to understand, decide, advance, persist, and complete affects cumulative investment, recovery cost, schedule exposure, and the number of completers produced by the same budget.
The industry has learned to price acquisition. It must now learn to value durability. When readiness becomes measurable, intervention becomes targeted. When intervention becomes attributable, its economic contribution becomes visible.
This publication is educational and does not provide medical, legal, regulatory, or financial advice. Trial-specific assumptions and value models require appropriate clinical, operational, financial, legal, privacy, and IRB review. © 2026 Jumo Health.